Agios Pharmaceuticals AGIO Operating Lease Income - 2025 (Lessor)

Operating Lease Income - 2025 (Lessor) at other companies

Bank of AmericaBAC

$303M-9.0%

The Travelers CompaniesTRV

$63M-12.5%

PNC Financial ServicesPNC

$12M-20.0%

PNC Financial ServicesPNC

$8M-33.3%

The Travelers CompaniesTRV

$46M0.0%

The Travelers CompaniesTRV

$92M-1.1%

Other financials

Income statement

See full

Revenue$20.7M+138%

Gross profit$19.4M+154%

Operating income-$110.0M-3.2%

Net income-$99.1M-11.0%

EPS (diluted)-$1.69-9.0%

Balance sheet

See full

Cash & equivalents$113.6M+43.9%

Total debt$35.7M-32.5%

Total equity$1.1B-24.4%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow-$118.9M-6.7%

CapEx$769.0K+0.4%

Free cash flow-$119.7M-6.6%

Valuation

See full

Market cap$2.16B+18.1%

Enterprise value$2.08B+15.2%

P/S32.7×-16.7×

Profitability

See full

Gross margin90%+2.5pp

Operating margin-720%-204pp

Net margin-639.8%—

FCF margin-582.5%-185pp

Returns & leverage

See full

Return on equity-32.8%—

Debt / equity0×0.0×

Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's operating lease income - 2025 (lessor).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Agios Pharmaceuticals's operating lease income - 2025 (lessor)?: Agios Pharmaceuticals (AGIO) reported operating lease income - 2025 (lessor) of $394K in Q1 2026.